2024
Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis
Ilagan-Ying Y, Gordon K, Tate J, Lim J, Torgersen J, Re V, Justice A, Taddei T. Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis. JAMA Network Open 2024, 7: e2443608. PMID: 39504020, PMCID: PMC11541635, DOI: 10.1001/jamanetworkopen.2024.43608.Peer-Reviewed Original ResearchConceptsClassification of DiseasesBody mass indexRisk scoreNinth Revision and International Statistical Classification of DiseasesMass indexAlcohol useInternational Statistical Classification of DiseasesStatistical Classification of DiseasesElectronic health recordsNon-Hispanic blacksInternational Classification of DiseasesNon-Hispanic whitesClinical Modification diagnosisHepatocellular carcinoma risk scoreRisk of hepatocellular carcinomaCox proportional hazards regression modelsValidation sampleHigh-risk individualsProportional hazards regression modelsHCC risk factorsFIB-4Multivariate risk scoreHepatocellular carcinomaHazards regression modelsViral hepatitisHepatitis Delta Virus Testing, Prevalence, and Liver-Related Outcomes Among U.S. Veterans with Chronic Hepatitis B
Wong R, Yang Z, Jou J, John B, Lim J, Cheung R. Hepatitis Delta Virus Testing, Prevalence, and Liver-Related Outcomes Among U.S. Veterans with Chronic Hepatitis B. Gastro Hep Advances 2024 DOI: 10.1016/j.gastha.2024.10.015.Peer-Reviewed Original ResearchChronic hepatitis B patientsChronic hepatitis BLiver-related outcomesHepatic decompensationHepatitis delta virusCohort of U.S. veteransNational cohortU.S. veteransRisk of cirrhosisIncidence of cirrhosisPositive patientsHDV infectionHepatitis BEvaluate incidenceHepatocellular carcinomaCirrhosisPatientsDecompensationVirus testingPropensity scoreHepatitisDelta virusNelson-Aalen methodDiagnosisOutcomesOutcomes of a 1‐Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B
Wong R, Liao M, Chen Y, Kwan M, Lee J, Jou J, Lim J, Cheung R. Outcomes of a 1‐Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B. Journal Of Viral Hepatitis 2024, 31: 768-770. PMID: 39101377, DOI: 10.1111/jvh.13992.Peer-Reviewed Original ResearchChronic hepatitis BAnti-HDVRNA testingHepatitis delta virusVeterans Affairs Health SystemUniversal testing approachAnti-HDV-positive patientsPilot studyChronic hepatitis B patientsProspective cohort studyHDV-RNA testsAnti-HDV antibodiesConsecutive CHB patientsRisk-based testingHealth systemDetectable HDV RNAChi-square testUS veteransDrug use historyCohort studyCirrhosis statusCHB patientsConsecutive adultsNo significant differenceAb positivitySevere Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidenceAssociation of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma
Yang Z, Cheung R, Jou J, Lim J, Lim Y, Wong R. Association of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma. Gastroenterology Research 2024, 17: 109-115. PMID: 38993547, PMCID: PMC11236339, DOI: 10.14740/gr1735.Peer-Reviewed Original ResearchBaseline HBV DNARisk of hepatocellular carcinomaChronic hepatitis BRisk of cirrhosisNon-cirrhotic chronic hepatitis BHepatitis B virus DNAHBV DNAHepatocellular carcinomaHepatitis B virusCHB patientsPropensity score weightingAntiviral therapyAssociated with higher risk of hepatocellular carcinomaHigh risk of hepatocellular carcinomaNon-cirrhotic CHB patientsCohort of CHB patientsLevels of hepatitis B virusContinuous antiviral therapyHigh HBV DNANon-Asian cohortModerate levelsAssociated with higher riskScore weightingB virus DNACox proportional hazards modelsIdentification of hepatic steatosis among persons with and without HIV using natural language processing
Torgersen J, Skanderson M, Kidwai-Khan F, Carbonari D, Tate J, Park L, Bhattacharya D, Lim J, Taddei T, Justice A, Re V. Identification of hepatic steatosis among persons with and without HIV using natural language processing. Hepatology Communications 2024, 8: e0468. PMID: 38896066, PMCID: PMC11186806, DOI: 10.1097/hc9.0000000000000468.Peer-Reviewed Original ResearchConceptsImaging ReportingSteatotic liver diseaseHIV statusHepatic steatosisPrevalence of metabolic comorbiditiesImaging studiesVeterans Aging Cohort StudyCompare patient characteristicsPositive predictive valueAlcohol use disorderAging Cohort StudyIdentification of hepatic steatosisHIV infectionHepatitis BMetabolic comorbiditiesNatural language processing algorithmsRadiological studiesCohort studyPatient characteristicsClinical reviewLiver diseaseHIVPredictive valueUse disorderClinical image reportsFRI-389 Hepatitis delta virus infection is associated with significantly greater incidence of cirrhosis and hepatic decompensation in U.S. veterans with chronic hepatitis B
Wong R, Yang Z, Jou J, John B, Lim J, Cheung R. FRI-389 Hepatitis delta virus infection is associated with significantly greater incidence of cirrhosis and hepatic decompensation in U.S. veterans with chronic hepatitis B. Journal Of Hepatology 2024, 80: s771. DOI: 10.1016/s0168-8278(24)02152-4.Peer-Reviewed Original ResearchEditorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
Njei B, Lim J. Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Alimentary Pharmacology & Therapeutics 2024, 60: 83-84. PMID: 38643498, DOI: 10.1111/apt.17951.Peer-Reviewed Original ResearchAn explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis
Njei B, Osta E, Njei N, Al-Ajlouni Y, Lim J. An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis. Scientific Reports 2024, 14: 8589. PMID: 38615137, PMCID: PMC11016071, DOI: 10.1038/s41598-024-59183-4.Peer-Reviewed Original ResearchConceptsNational Health and Nutrition Examination SurveyRisk of progression to cirrhosisClinical risk indexHealth and Nutrition Examination SurveyControlled attenuation parameter valuesNovel therapeutic optionsLiver stiffness measurementProgression to cirrhosisAspartate aminotransferase levelsNutrition Examination SurveyResource-limited settingsFIB-4Fibrosis scorePlatelet countAminotransferase levelsTherapeutic optionsWaist circumferenceClinically applicable modelExamination SurveyNonalcoholic steatohepatitisFAST scoreEarly identificationElastography measurementsStiffness measurementPatientsAdvances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents
Lam R, Lim J. Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents. World Journal Of Hepatology 2024, 16: 331-343. PMID: 38577537, PMCID: PMC10989302, DOI: 10.4254/wjh.v16.i3.331.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsFunctional cure of chronic hepatitis BCure of chronic hepatitis BNovel investigational agentsChronic hepatitis BFunctional cureHepatitis B virusInvestigational agentsHepatitis BSuppression of HBV DNARisk of liver complicationsChronic hepatitis B virusAssociated with significant morbidityToll-like receptor agonistsOral nucleos(t)ide analoguesHepatitis B surface antigenB surface antigenLong-term treatmentAssociated with higher ratesMortality due to cirrhosisCheckpoint inhibitorsNucleos(t)ide analoguesVirologic suppressionPhase IIAntiviral regimensIII trials
2023
Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database
Gish R, Jacobson I, Lim J, Waters-Banker C, Kaushik A, Kim C, Cyhaniuk A, Wong R. Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database. Hepatology 2023, 79: 1117-1128. PMID: 37976395, PMCID: PMC11020024, DOI: 10.1097/hep.0000000000000687.Peer-Reviewed Original ResearchConceptsHBV/HDV infectionLiver complicationsAll-Payer Claims DatabaseClaims databaseRisk of liver-related morbidityHepatitis delta virus infectionPrevalence of HDVDelta virus infectionProportion of patientsTime of diagnosisLiver-related morbidityUS insured populationHDV prevalenceHBV populationsHIV infectionCompensated cirrhosisDecompensated cirrhosisHBV infectionDelayed diagnosisHDV infectionHepatitis BViral hepatitisHBV/HDVPatient characteristicsSevere formPrecipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals
Malhi H, Brown R, Lim J, Reau N, Tapper E, Wong C, Gores G. Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Liver Transplantation 2023, 29: 1262-1263. PMID: 37941408, DOI: 10.1097/lvt.0000000000000279.Peer-Reviewed Original ResearchPrecipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals
Malhi H, Brown R, Lim J, Reau N, Tapper E, Wong C, Gores G. Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatology Communications 2023, 7: e0318. PMID: 37941420, PMCID: PMC10635597, DOI: 10.1097/hc9.0000000000000318.Peer-Reviewed Original ResearchPrecipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals
Malhi H, Brown R, Lim J, Reau N, Tapper E, Wong C, Gores G. Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatology 2023, 78: 1680-1681. PMID: 37941421, DOI: 10.1097/hep.0000000000000619.Peer-Reviewed Original ResearchPrecipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals
Malhi H, Brown R, Lim J, Reau N, Tapper E, Wong C, Gores G. Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Clinical Liver Disease 2023, 22: 193-194. PMID: 38143807, PMCID: PMC10745227, DOI: 10.1097/cld.0000000000000094.Peer-Reviewed Original ResearchClinical and Histopathological Discoveries in Patients with Hepatic Injury and Cholangiopathy Who Have Died of COVID-19: Insights and Opportunities for Intervention
Lim J, Njei B. Clinical and Histopathological Discoveries in Patients with Hepatic Injury and Cholangiopathy Who Have Died of COVID-19: Insights and Opportunities for Intervention. Hepatic Medicine Evidence And Research 2023, 15: 151-164. PMID: 37814605, PMCID: PMC10560482, DOI: 10.2147/hmer.s385133.Peer-Reviewed Original ResearchAcute liver injuryCOVID-19 patientsPre-existing chronic liver diseaseCOVID-19Chronic liver diseaseSARS-CoV-2Immune dysregulationSupportive careBiliary dysfunctionHepatic injuryLiver injuryVascular changesLiver diseaseClinical manifestationsSignificant complicationsLong-term effectsDiagnostic criteriaTherapeutic targetCholangiopathyDiagnostic advancementsPatientsGlobal healthCOVID-19 pandemicInjuryDiverse manifestationsScreening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Ilagan-Ying Y, Banini B, Do A, Lam R, Lim J. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Current Gastroenterology Reports 2023, 25: 213-224. PMID: 37768417, DOI: 10.1007/s11894-023-00883-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseLiver diseaseCommon chronic liver diseaseNonalcoholic fatty liver diseaseCurrent expert guidelinesHigh-risk patientsChronic liver diseaseSteatotic liver diseaseClinical practice implicationsHepatic decompensationLiver biopsySociety guidelinesSpecialty referralsNovel therapiesExpert guidelinesLiver cancerDisease awarenessObesity epidemicSerum indicesClinical practiceScreening toolDiseaseDiagnosisExercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Chen G, Banini B, Do A, Gunderson C, Zaman S, Lim J. Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Genes 2023, 14: 1811. PMID: 37761951, PMCID: PMC10531443, DOI: 10.3390/genes14091811.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseEffects of exerciseFatty liver diseaseHistological outcomesLiver histologyLiver diseaseClinical trialsHistological endpointsSystematic reviewSignificant histopathological improvementNAFLD activity scoreImpact of exerciseIndependent effectsRandom-effects modelSystematic literature searchHistopathological improvementExercise interventionActivity scoreClinical endpointsPooled estimatesMeta-AnalysisTotal participantsLiterature searchComparison groupHepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016
Kim J, Newcomb C, Carbonari D, Torgersen J, Althoff K, Kitahata M, Klein M, Moore R, Reddy K, Silverberg M, Mayor A, Horberg M, Cachay E, Lim J, Gill M, Chew K, Sterling T, Hull M, Seaberg E, Kirk G, Coburn S, Lang R, McGinnis K, Gebo K, Napravnik S, Kim H, Re V, Research and Design of IeDEA F. Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016. PLOS ONE 2023, 18: e0290889. PMID: 37656704, PMCID: PMC10473492, DOI: 10.1371/journal.pone.0290889.Peer-Reviewed Original ResearchConceptsNorth American AIDS Cohort CollaborationUndetectable HBV DNAHBV coinfectionHBV DNACare cascadeCohort CollaborationViral suppressionHIV/HBV coinfectionTenofovir-based antiretroviral therapyHIV/HBVAntiretroviral therapy regimenCross-sectional studyDelivery of careHBV therapyHBV treatmentHBV viremiaAntiretroviral therapyHBV infectionHIV infectionTherapy regimenChronic infectionClinical cohortCoinfectionTherapyInfectionSa1523 ON-TREATMENT RISK OF HEPATOCELLULAR CARCINOMA DOES NOT DIFFER BY BASELINE HEPATITIS B VIRAL LOAD AMONG A LARGE COHORT OF PREDOMINANTLY NON-ASIAN PATIENTS WITH NON-CIRRHOTIC E ANTIGEN NEGATIVE CHRONIC HEPATITIS B
Yang Z, Cheung R, Jou J, Lim J, Wong R. Sa1523 ON-TREATMENT RISK OF HEPATOCELLULAR CARCINOMA DOES NOT DIFFER BY BASELINE HEPATITIS B VIRAL LOAD AMONG A LARGE COHORT OF PREDOMINANTLY NON-ASIAN PATIENTS WITH NON-CIRRHOTIC E ANTIGEN NEGATIVE CHRONIC HEPATITIS B. Gastroenterology 2023, 164: s-399-s-400. DOI: 10.1016/s0016-5085(23)01924-8.Peer-Reviewed Original Research